Reprint of: The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide

International Journal of Orthopaedic and Trauma Nursing

Volumn 26, Issue , 2017, Pages 7-17

  Curtis, Elizabeth M ^a   Moon, Rebecca J ^a,b   Harvey, Nicholas C ^a,b   Cooper, Cyrus ^a,b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Assessment; Epidemiology; Geography; High fracture risk; Osteoporosis

Indexed keywords

EID: 85020128331     PISSN: 18781241     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijotn.2017.04.004     Document Type: Article

References (94)

1. Abrahamsen, B., et al. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. Bmj, 353, 2016, i3365.
2. Adler, R.A., et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for bone and mineral research. J. Bone Min. Res. 31:1 (2016), 16–35.
3. Akesson, K., et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos. Int. 24:8 (2013), 2135–2152.
4. Araujo, A.B., et al. Race/ethnic differences in bone mineral density in men. Osteoporos. Int. 18:7 (2007), 943–953.
5. Bacon, W.E., Hadden, W.C., Occurrence of hip fractures and socioeconomic position. J. Aging Health 12:2 (2000), 193–203.
6. Bengner, U., Johnell, O., Redlund-Johnell, I., Changes in incidence and prevalence of vertebral fractures during 30 years. Calcif. Tissue Int. 42:5 (1988), 293–296.
7. Bone Health and Osteoporosis: A Report of the Surgeon General, 2004 (Rockville MD).
8. Cauley, J.A., et al. Official positions for FRAX(R) clinical regarding international differences from joint official positions development conference of the international society for clinical densitometry and international osteoporosis foundation on FRAX(R). J. Clin. Densitom. 14:3 (2011), 240–262.
9. Clark, E.M., et al. Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: cohort for Skeletal Health in Bristol and Avon (COSHIBA). J. Bone Min. Res. 27:3 (2012), 664–671.
10. Clark, E.M., Gooberman-Hill, R., Peters, T.J., Using self-reports of pain and other variables to distinguish between older women with back pain due to vertebral fractures and those with back pain due to degenerative changes. Osteoporos. Int. 27:4 (2016), 1459–1467.
11. Compston, J., et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: national Osteoporosis Guideline Group (NOGG) update 2013. Maturitas, 2013.
12. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94:6 (1993), 646–650.
13. Cooper, C., Harvey, N.C., Osteoporosis risk assessment. BMJ, 344, 2012, e4191.
14. Cooper, C., Campion, G., Melton, L.J., Hip fractures in the elderly: a world-wide projection. Osteoporos. Int. 2:6 (1992), 285–289.
15. Cooper, C., et al. Secular trends in the incidence of postmenopausal vertebral fractures. Calcif. Tissue Int. 51:2 (1992), 100–104.
16. Cooper, C., et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J. Bone Min. Res. 7:2 (1992), 221–227.
17. Cooper, C., et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos. Int. 22:5 (2011), 1277–1288.
18. Cosman, F., et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos. Int. 25:10 (2014), 2359–2381.
19. Curtis, E.M., et al. Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87 (2016), 19–26.
20. Drew, S., et al. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos. Int. 27:5 (2016), 1719–1727.
21. Eisman, J.A., et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J. Bone Min. Res. 27:10 (2012), 2039–2046.
22. Elffors, I., et al. The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos. Int. 4:5 (1994), 253–263.
23. Giangregorio, L., et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin. Arthritis Rheum. 35:5 (2006), 293–305.
24. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:9995 (2015), 743–800.
25. Goh, J.C., Low, S.L., Das De, S., Bone mineral density and hip axis length in Singapore's multiracial population. J. Clin. Densitom. 7:4 (2004), 406–412.
26. Greenspan, S.L., et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J. Am. Geriatr. Soc. 60:3 (2012), 455–461.
27. Gregson, C.L., et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos. Int. 25:1 (2014), 85–95.
28. Grover, M.L., et al. Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk. Womens Health Issues 24:1 (2014), e69–75.
29. Gullberg, B., Johnell, O., Kanis, J.A., World-wide projections for hip fracture. Osteoporos. Int. 7:5 (1997), 407–413.
30. Harvey, N.C., et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos. Int. 27:1 (2016), 267–274.
31. Hernlund, E., et al. Osteoporosis in the European union: medical management, epidemiology and economic burden: a report prepared in collaboration with the international osteoporosis foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA). Arch. Osteoporos., 8(1–2), 2013, 136.
32. Hippisley-Cox, J., Coupland, C., Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ, 339, 2009, b4229.
33. Hippisley-Cox, J., Coupland, C., Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. Bmj, 344, 2012, e3427.
34. Hippisley-Cox, J., Coupland, C., Brindle, P., The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open, 4(8), 2014, e005809.
35. Islam, S., et al. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 16:1 (2009), 77–83.
36. Johnell, O., et al. Risk factors for hip fracture in European women: the MEDOS study. Mediterranean osteoporosis study. J. Bone Min. Res. 10:11 (1995), 1802–1815.
37. Johnell, O., et al. Predictive value of BMD for hip and other fractures. J.Bone Miner.Res. 20:7 (2005), 1185–1194.
38. Johnell, O., et al. Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos. Int. 18:3 (2007), 333–337.
39. Kanis, J.A., Passmore, R., Calcium supplementation of the diet–I. Bmj 298:6667 (1989), 137–140.
40. Kanis, J.A., Passmore, R., Calcium supplementation of the diet–II. Bmj 298:6668 (1989), 205–208.
41. Kanis, J.A., et al. Smoking and fracture risk: a meta-analysis. Osteoporos. Int. 16:2 (2005), 155–162.
42. Kanis, J.A., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18:8 (2007), 1033–1046.
43. Kanis, J.A., et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19:4 (2008), 385–397.
44. Kanis, J.A., et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22:11 (2011), 2789–2798.
45. Kanis, J.A., et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 22:3 (2011), 809–816.
46. Kanis, J.A., et al. Interpretation and use of FRAX in clinical practice. Osteoporos. Int. 22:9 (2011), 2395–2411.
47. Kanis, J.A., et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos. Int. 23:9 (2012), 2239–2256.
48. Kanis, J.A., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 24:1 (2013), 23–57.
49. Kanis, J.A., et al. SCOPE: a scorecard for osteoporosis in Europe. Arch. Osteoporos., 8, 2013, 144.
50. Kanis, J.A., et al. Worldwide uptake of FRAX. Arch. Osteoporos., 9(1), 2014, 166.
51. Kanis, J.A., et al. The osteoporosis treatment gap. J. Bone Min. Res. 29:9 (2014), 1926–1928.
52. Kanis, J.A., et al. SIGN guidelines for Scotland: BMD versus FRAX versus QFracture. Calcif. Tissue Int. 98:5 (2016), 417–425.
53. Kanis, J.A., et al. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch. Osteoporos., 11(1), 2016, 25.
54. Kim, T.Y., et al. Trends of incidence, mortality, and future projection of spinal fractures in korea using nationwide claims Data. J. Korean Med. Sci. 31:5 (2016), 801–805.
55. Koh, L.K., et al. Hip fracture incidence rates in Singapore 1991-1998. Osteoporos. Int. 12:4 (2001), 311–318.
56. Lau, E.M., et al. Hip fracture in Hong Kong over the last decade–a comparison with the UK. J. Public Health Med. 21:3 (1999), 249–250.
57. Lekamwasam, S., et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 23:9 (2012), 2257–2276.
58. Lekamwasam, S., et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch. Osteoporos. 7:1–2 (2012), 25–30.
59. Leslie, W.D., Schousboe, J.T., A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr. Osteoporos. Rep. 9:3 (2011), 129–140.
60. Leslie, W.D., et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos. Int. 23:1 (2012), 75–85.
61. Leslie, W.D., et al. Does osteoporosis therapy invalidate FRAX for fracture prediction?. J. Bone Min. Res. 27:6 (2012), 1243–1251.
62. Looker, A.C., et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J. Bone Min. Res. 25:1 (2010), 64–71.
63. Marshall, D., Johnell, O., Wedel, H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:7041 (1996), 1254–1259.
64. McCloskey, E., L.E, Clarke, S., Fordham, R., Gittoes, N., Harvey, I., Holland, R., Howe, A., Marshall, T., Peters, T., Kanis, J., O'Neill, T., Torgerson, D., Cooper, C., Shepstone, L., Screening based on FRAX fracture risk assessment reduces the incidence of hip fractures in older community-dwelling women – results from the SCOOP study: abstracts of Osteoporosis Conference 2016. Osteoporos. Int. 27:2 (2016), 609–685.
65. McCloskey, E.V., et al. FRAX updates 2016. Curr. Opin. Rheumatol. 28:4 (2016), 433–441.
66. Mitchell, P.J., Best practices in secondary fracture prevention: fracture liaison services. Curr. Osteoporos. Rep. 11:1 (2013), 52–60.
67. Mitchell, P., et al. Implementation of models of care for secondary osteoporotic fracture prevention and orthogeriatric models of care for osteoporotic hip fracture. Best. Pract. Res. Clin. Rheumatol. 30:3 (2016), 536–558.
68. Moon, R.J., Harvey, N.C., Identification of patient profile for treatment. Best. Pract. Res. Clin. Endocrinol. Metab. 28:6 (2014), 767–782.
69. Murray, C.J., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 386:10009 (2015), 2145–2191.
70. National Osteoporosis Foundation. Clinician's Guide to the Prevention and Treatment of Osteoporosis, 2013, National Osteoporosis foundation, Washington DC.
71. Nations, U., World Population Prospects: the 2015 Revision. 2015, United Nations, New York.
72. Nguyen, N.D., et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos. Int. 19:10 (2008), 1431–1444.
73. Oden, A., et al. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos. Int. 26:9 (2015), 2243–2248.
74. Olmez Sarikaya, N., et al. Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clin. Rheumatol., 2014.
75. Overman, R.A., et al. DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women. J. Clin. Densitom. 18:2 (2015), 145–149.
76. Putman, M.S., et al. Differences in skeletal microarchitecture and strength in African-American and white women. J. Bone Min. Res. 28:10 (2013), 2177–2185.
77. Shepstone, L., et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos. Int. 23:10 (2012), 2507–2515.
78. Siggeirsdottir, K., et al. Epidemiology of fractures in Iceland and secular trends in major osteoporotic fractures 1989-2008. Osteoporos. Int. 25:1 (2014), 211–219.
79. Silverman, S.L., Madison, R.E., Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California hospital discharge data. Am. J. Public Health 78:11 (1988), 1482–1483.
80. Solomon, L., Osteoporosis and fracture of the femoral neck in the South African Bantu. J. Bone Jt. Surg. Br. 50:1 (1968), 2–13.
81. Solomon, D.H., et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J. Bone Min. Res. 29:9 (2014), 1929–1937.
82. Srinivasan, B., et al. Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. Osteoporos. Int. 23:1 (2012), 155–162.
83. The Eastern European & Central Asian Regional Audit Epidemiology, Costs & Burden of Osteoporosis in 2010, 2011, International Osteoporosis Foundation, Nyon.
84. Tsukutani, Y., et al. Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis. Osteoporos. Int. 26:9 (2015), 2249–2255.
85. van der Velde, R.Y., et al. Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporos. Int., 2016.
86. van der Velde, R.Y., et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone 94 (2016), 50–55.
87. van Staa, T.P., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol. Oxf. 39:12 (2000), 1383–1389.
88. van Staa, T.P., et al. Use of oral corticosteroids and risk of fractures. J. Bone Min. Res. 15:6 (2000), 993–1000 JID - 8610640.
89. van Staa, T.P., et al. Epidemiology of fractures in England and Wales. Bone 29:6 (2001), 517–522.
90. Wainwright, S.A., et al. Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 90:5 (2005), 2787–2793.
91. World Health Organization Study, G., Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis, 1994.
92. Wright, N.C., et al. Recent trends in hip fracture rates by race/ethnicity among older US adults. J. Bone Min. Res. 27:11 (2012), 2325–2332.
93. Xu, L., et al. Very low rates of hip fracture in Beijing, People's Republic of China the Beijing Osteoporosis project. Am. J. Epidemiol. 144:9 (1996), 901–907.
94. Yang, P.L., et al. Associations between ethnicity, body composition, and bone mineral density in a Southeast Asian population. J. Clin. Endocrinol. Metab. 98:11 (2013), 4516–4523.